Alzheimer's disease (AD) is associated with cognitive dysfunction. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Research
28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
Alzheimer's disease (AD), the most common form of dementia, is a leading cause of death and a major cause of morbidity in older people. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease is a common and devastating disease characterized by aggregation of the amyloid-β peptide. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
PLWD and carers need to receive specific practical and psychological support during the pandemic to support their well-being, which is severely affected by public health restrictions. 2 key findings →
Participants: 42 Evidence: low
Full summary, score breakdown and related studies → Original source
We performed an observational analysis of prospectively collected data on 1,474 adult patients who were hospitalized for community-acquired pneumonia; 1,169 patients were under 80 years of age and 305 (21%) patients were over 80 years ("very elderly"). 5 key findings →
Participants: 1,169 Evidence: low
Full summary, score breakdown and related studies → Original source
In this cohort of hospitalized patients with advanced dementia, risk of receiving a new feeding tube is high, associated with African American ethnicity, and prior residence in a nursing home, and has no measurable influence on survival. 4 key findings →
Participants: 99 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Persons with moderate dementia demonstrated variability in how they participated in decision making. 3 key findings →
Participants: 30 Evidence: low
Full summary, score breakdown and related studies → Original source
Recovery rates are low, even among those with higher levels of pre-fracture functional status, and are worse for patients who are older, cognitively impaired, and who have multiple comorbidities. 3 key findings →
Participants: 733 Evidence: low
Full summary, score breakdown and related studies → Original source
The prevalence ratio of many common psychiatric and somatic conditions is increased in adults with epilepsy who consult a primary care physician in the U.K. These findings may have implications in the diagnosis and management of epilepsy and coexisting conditions, as well as in health care provision. 3 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source
There is no consensus for a blood-based test for the early diagnosis of Alzheimer's disease (AD). 3 key findings →
Participants: 49 Evidence: low
Full summary, score breakdown and related studies → Original source
47/100
To evaluate the utility of arterial spin-labeled blood flow magnetic resonance imaging for the detection of cerebral blood flow abnormalities in Alzheimer's disease, arterial spin-labeled blood flow images in 16 contiguous 5-mm axial sections were acquired in 18 patients diagnosed with probable Alzheimer's disease and 11 age-matched controls. 1 key finding →
Participants: 18 Evidence: low
Full summary, score breakdown and related studies → Original source
We investigated the range of behavioral abnormalities in patients with Alzheimer's disease (AD) compared with normal age-matched control subjects. 3 key findings →
Participants: 17 Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease research has largely concentrated on the study of cognitive decline, but the associated behavioural and neuropsychiatric symptoms are of equal importance in the clinical profile of the disease. 4 key findings →
Participants: 31 Evidence: low
Full summary, score breakdown and related studies → Original source
With decreasing local and global connectivity parameters, the large-scale functional brain network organization in AD deviates from the optimal 'small-world' network structure towards a more 'random' type. 5 key findings →
Participants: 20 Evidence: low
Full summary, score breakdown and related studies → Original source
Confrontation naming is impaired in neurodegenerative conditions like Alzheimer's disease (AD), frontotemporal dementia (FTD) and corticobasal degeneration (CBD). 3 key findings →
Participants: 50 Evidence: low
Full summary, score breakdown and related studies → Original source
Worldwide, there are nearly 10 million new cases of dementia annually, of which Alzheimer's disease (AD) is the most common. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
A panel of possible CSF biomarkers for AD has been identified using proteomic methods. 1 key finding →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Whether initiation of statins could increase survival free of dementia and disability in adults aged ≥75 years is unknown. 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source
Utilization and costs for patients with AD were higher compared to controls and were substantially higher for patients with both AD and co-morbid diseases commonly targeted for disease management. 5 key findings →
Participants: 1,366 Evidence: low
Full summary, score breakdown and related studies → Original source
The authors identified several factors, including receipt of mechanical ventilation, which were significantly associated with increased long-term mortality for survivors of severe sepsis. 5 key findings →
Participants: 2,727 Evidence: low
Full summary, score breakdown and related studies → Original source
The burden of dementia in Korea is expected to considerably increase alongside the elderly population in the future. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Using pre-trained language models can improve AD prediction. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Metformin, a diabetes drug with anti-aging cellular responses, has complex actions that may alter dementia onset. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
We determined the effects of distraction on gait in healthy elderly subjects and Alzheimer's disease (AD) patients. 5 key findings →
Participants: 20 Evidence: low
Full summary, score breakdown and related studies → Original source
Conductance to outflow of CSF was measured in a prospective study of 80 patients with normal pressure hydrocephalus. 3 key findings →
Participants: 80 Evidence: low
Full summary, score breakdown and related studies → Original source
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →